AES Annual Meeting 2025
DAY 1 | Individuals with Focal Epilepsy Achieved Long-Term Seizure Freedom with Azetukalner
A post-hoc analysis from the open-label extension of a phase 2b trial enrolling adults with focal onset seizures (FOS) showed that azetukalner, a Kv7 potassium channel opener, helped patients achieve long periods of seizure freedom and regain seizure control after breakthrough seizures.
December 15, 2025
Read more
DAY 1 | Depression Symptoms Increase Disease Burden for Patients with Focal Onset Seizures
Findings from a survey reflecting patient-reported outcomes showed that depression symptoms affect quality of life and increase healthcare resource utilization for individuals diagnosed with focal onset seizures (FOS), who experience a significant but underrecognized mental health burden.
December 15, 2025
Read more
DAY 1 | Minimally Invasive Laser Ablation Provides Durable Results in the Treatment of Refractory Temporal Lobe Epilepsy
Laser interstitial thermal therapy (LITT) achieved sustained reductions in seizure activity in patients with drug-resistant mesial temporal lobe epilepsy, according to an analysis featured at the 2025 American Epilepsy Society Annual Meeting, in Atlanta, Georgia.
December 15, 2025
Read more
DAY 1 | Patients and Providers Struggle with the Complex Titration Schedules of Anti-Seizure Medications
The titration of anti-seizure medications presents a complex clinical challenge for patients with focal epilepsy and the physicians who manage their care, according to findings from a study presented at the 2025 American Epilepsy Society Annual Meeting, in Atlanta, Georgia.
December 15, 2025
Read more
© 2025 Wolters Kluwer. All right reserved.